ANNEXON, INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
ANNEXON, INC. (ANNX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $1.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- ANNEXON, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $1.00K.
- ANNEXON, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $0.00.
- ANNEXON, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$12.00K.
- ANNEXON, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$5.00K, a 266.67% decline year-over-year.
- ANNEXON, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $2.00K.
- ANNEXON, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$15.00K, a 400.00% decline from fiscal 2023.
- ANNEXON, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $5.00K, a 400.00% increase from fiscal 2022.
- ANNEXON, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was $1.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $1.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $2.00K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $2.00K 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $2.00K 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$15.00K 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$9.00K 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | -$11.00K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$12.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $5.00K 10-K · filed 2025-03-03 | |||
| 2023-09-30 | -$8.00K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$6.00K 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | -$5.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $1.00K 10-K · filed 2024-03-26 | |||
| 2022-09-30 | -$7.00K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$3.00K 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | $3.00K 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$5.00K 10-K · filed 2023-03-06 | |||
| 2021-09-30 | -$5.00K 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$2.00K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$1.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $9.00K 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $2.00K 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | -$2.00K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$11.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |